Funding Partnerships Strong funding momentum and strategic alliances position Pathalys for accelerated late-stage development and potential co-development or licensing deals. With a $105 million Series B raised in 2024 and collaborations with Abingworth, Launch Therapeutics, and DaVita, Pathalys demonstrates readiness to engage partners across clinical development, manufacturing, and commercialization.

Pre-Commercial Readiness Phase 3 program for upacicalet and pre-commercialization activities indicate imminent launch readiness. Opportunities exist to engage CMOs for manufacturing scale, regulatory and market-access consultancies, and partnerships that support registration, pricing, and payer strategies.

Nephrology Ecosystem Pathalys' focus on end-stage renal disease and the DaVita partnership provides access to dialysis centers, nephrology clinics, and patient communities for trial recruitment, real-world evidence generation, and post-approval uptake programs.

Tech and Data While Pathalys' current tech stack is web and data oriented, business development opportunities include partnerships with CROs and software vendors offering secure data management, clinical trial software (EDC, PV), cloud hosting, and digital tools that enhance CKD patient care workflows.

Clinical Leadership Recent leadership additions, including the Chief Medical Officer appointment, signal a strong emphasis on clinical development and regulatory strategy, creating avenues for medical affairs outsourcing, KOL engagement programs, and payer-facing strategic services.